Page last updated: 2024-11-05

thalidomide and Ache

thalidomide has been researched along with Ache in 40 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

ExcerptRelevanceReference
"Apremilast, an oral, small-molecule phosphodiesterase 4 inhibitor, has demonstrated efficacy in patients with moderate-to-severe psoriasis."9.24The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). ( Bewley, A; Day, RM; Goncalves, J; Gooderham, M; Green, L; Khanskaya, I; Piguet, V; Reich, K; Shah, K; Soung, J; Zhang, Z, 2017)
" The effects of apremilast, an oral phosphodiesterase inhibitor, on pruritus, skin discomfort/pain, and patient global assessment of psoriasis disease activity (PgAPDA) were assessed in moderate/severe chronic plaque psoriasis patients in the phase 3 ESTEEM trials."9.22Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis. ( Chen, R; Day, RM; Foley, P; Girolomoni, G; Goncalves, J; Mrowietz, U; Sobell, JM; Toth, D; Yosipovitch, G, 2016)
"Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma."9.22Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016)
"For several decades, the treatment of elderly patients with multiple myeloma (MM) has consisted of melphalan and prednisone (MP)."9.14Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. ( Ammerlaan, R; Lokhorst, H; Schaafsma, M; Sinnige, H; Sonneveld, P; Termorshuizen, F; van der Griend, R; van Marwijk Kooy, M; Wijermans, P; Wittebol, S; Zweegman, S, 2010)
"Good response to combined pamidronate and thalidomide therapy can be expected in at least 50% of patients with treatment-resistant multiple myeloma with advanced osteolytic lesions."9.10Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002)
"This report-the second of a series on codeine and its alternates for pain and cough relief-contains a detailed evaluation of experimental and clinical data on newer substances having analgesic properties comparable to and in approximately the same range as those of codeine."8.74Codeine and its alternates for pain and cough relief. 2. Alternates for pain relief. ( Eddy, NB; Friebel, H; Hahn, KJ; Halbach, H, 1969)
"The aim of this study was to assess psychological/psychiatric problems and quality of life (QOL) in patients with thalidomide embryopathy (TE), with a specific focus on pain, including pain severity and the effects of coping strategies for pain."7.96Quality of life and pain in patients with thalidomide embryopathy in Japan. ( Hinoshita, F; Imai, K; Nakano, Y; Otomo, K; Sone, H, 2020)
"Targeting of peripheral TRPA1 and central TRPV4 may be required to attenuate pain associated with CIPN elicited by thalidomide and related drugs."7.96Oxidative stress mediates thalidomide-induced pain by targeting peripheral TRPA1 and central TRPV4. ( Coppi, E; De Logu, F; De Siena, G; Geppetti, P; Landini, L; Li Puma, S; Marini, M; Marone, IM; Materazzi, S; Nassini, R; Padilha Dalenogare, D; Souza Monteiro de Araujo, D; Titiz, M; Trevisan, G, 2020)
"These results suggest that thalidomide can efficiently alleviate bone cancer pain and it may be a useful alternative or adjunct therapy for bone cancer pain."7.76Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-α expression in a mouse model. ( Gu, X; Ma, Z; Mei, F; Ren, B; Zhang, J; Zhang, R; Zheng, Y, 2010)
"In an open study, 17 patients (16 women, 1 man) with refractory or severe rheumatoid arthritis were treated with thalidomide."7.67Treatment of refractory rheumatoid arthritis--the thalidomide experience. ( Gutiérrez-Montes, O; Gutiérrez-Rodríguez, O; Starusta-Bacal, P, 1989)
"Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24."6.78Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013)
" Phase 2 dosing was determined to be bortezomib 1."6.75Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. ( Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W, 2010)
"At diagnosis, although bone resorption markers were increased in more than 40% of the patients, only NTX (P = 0."6.72First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. ( Baccarani, M; Boni, P; Cangini, D; Cavo, M; Ceccolini, M; Cellini, C; Parente, R; Perrone, G; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2006)
"Thalidomide was introduced as a sedative and antiemetic agent to the European market in the late 1950s."6.42[Novel potential uses of thalidomide in the management of pain? A review of the literature]. ( Bruera, E; Peuckmann, V; Strumpf, M; Zenz, M, 2003)
"During maintenance medication at the fourth and eighth weekend, the two doses (50 and 25 mg/d) of thalidomide were equivalent in reducing the incidence of ulcers, ulcer number, and ulcer pain, respectively (all p > 0."5.51A Randomized controlled clinical trial on dose optimization of thalidomide in maintenance treatment for recurrent aphthous stomatitis. ( Deng, Y; Du, G; Pan, L; Tang, G; Wang, Y; Wei, W; Yao, H, 2022)
" Pearson's correlation coefficients assessed relationships between efficacy endpoints (oral ulcer count, oral ulcer pain, Behçet's Syndrome Activity Scale (BSAS), Behçet's Disease Current Activity Form (BDCAF)) and QoL endpoints for apremilast at Week 12."5.51Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study. ( Chen, M; Cheng, S; Hatemi, G; Kim, D; Mahr, A; McCue, S; Melikoğlu, M; Paris, M; Takeno, M; Yazici, Y, 2022)
"Thalidomide has been shown to selectively inhibit TNF-alpha production."5.31Analgesic effect of thalidomide on inflammatory pain. ( Cunha, FQ; Ferreira, SH; Ribeiro, RA; Vale, ML, 2000)
"Apremilast, an oral, small-molecule phosphodiesterase 4 inhibitor, has demonstrated efficacy in patients with moderate-to-severe psoriasis."5.24The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). ( Bewley, A; Day, RM; Goncalves, J; Gooderham, M; Green, L; Khanskaya, I; Piguet, V; Reich, K; Shah, K; Soung, J; Zhang, Z, 2017)
" The effects of apremilast, an oral phosphodiesterase inhibitor, on pruritus, skin discomfort/pain, and patient global assessment of psoriasis disease activity (PgAPDA) were assessed in moderate/severe chronic plaque psoriasis patients in the phase 3 ESTEEM trials."5.22Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis. ( Chen, R; Day, RM; Foley, P; Girolomoni, G; Goncalves, J; Mrowietz, U; Sobell, JM; Toth, D; Yosipovitch, G, 2016)
"Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma."5.22Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016)
"For several decades, the treatment of elderly patients with multiple myeloma (MM) has consisted of melphalan and prednisone (MP)."5.14Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. ( Ammerlaan, R; Lokhorst, H; Schaafsma, M; Sinnige, H; Sonneveld, P; Termorshuizen, F; van der Griend, R; van Marwijk Kooy, M; Wijermans, P; Wittebol, S; Zweegman, S, 2010)
"Good response to combined pamidronate and thalidomide therapy can be expected in at least 50% of patients with treatment-resistant multiple myeloma with advanced osteolytic lesions."5.10Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002)
"Thalidomide and bortezomib are remarkably efficacious in the treatment of multiple myeloma."4.85Multiple myeloma, painful neuropathy, acupuncture? ( Chang, DZ; Chiang, J; Delasalle, K; Fang, W; Forman, A; Garcia, MK; Guo, Y; Lu, J; Romaguera, J; Wang, M; Yi, Q; Zhou, Y, 2009)
"Dramatic relief of pain and life-altering changes in quality of life in some patients treated with immunomodulators such as thalidomide compel us to look more closely at unconventional mechanisms that may be involved in propagation of persistent pain."4.84Does thalidomide have an analgesic effect? Current status and future directions. ( Goli, V, 2007)
"This report-the second of a series on codeine and its alternates for pain and cough relief-contains a detailed evaluation of experimental and clinical data on newer substances having analgesic properties comparable to and in approximately the same range as those of codeine."4.74Codeine and its alternates for pain and cough relief. 2. Alternates for pain relief. ( Eddy, NB; Friebel, H; Hahn, KJ; Halbach, H, 1969)
"As individuals with thalidomide embryopathy now reaching their 60's they undergo long-term sequelae of their prenatal damage and experience a wide range of secondary health problems, in particular chronic musculoskeletal pain, movement restrictions, and mental disorders."4.12Health-related quality of life after 50 years in individuals with thalidomide embryopathy: Evidence from a German cross-sectional survey. ( Alayli, A; Albus, C; Lüngen, M; Niecke, A; Peters, KM; Pfaff, H; Samel, C, 2022)
"Targeting of peripheral TRPA1 and central TRPV4 may be required to attenuate pain associated with CIPN elicited by thalidomide and related drugs."3.96Oxidative stress mediates thalidomide-induced pain by targeting peripheral TRPA1 and central TRPV4. ( Coppi, E; De Logu, F; De Siena, G; Geppetti, P; Landini, L; Li Puma, S; Marini, M; Marone, IM; Materazzi, S; Nassini, R; Padilha Dalenogare, D; Souza Monteiro de Araujo, D; Titiz, M; Trevisan, G, 2020)
"The aim of this study was to assess psychological/psychiatric problems and quality of life (QOL) in patients with thalidomide embryopathy (TE), with a specific focus on pain, including pain severity and the effects of coping strategies for pain."3.96Quality of life and pain in patients with thalidomide embryopathy in Japan. ( Hinoshita, F; Imai, K; Nakano, Y; Otomo, K; Sone, H, 2020)
"Morphine is a μ-opioid analgesic drug which is used in the treatment and management of chronic pain."3.85Thalidomide attenuates the development and expression of antinociceptive tolerance to μ-opioid agonist morphine through l-arginine-iNOS and nitric oxide pathway. ( Dehpour, AR; Ejtemaei-Mehr, S; Hassanipour, M; Khan, MI; Moghaddaskho, F; Momeny, M; Mumtaz, F; Ostadhadi, S, 2017)
"These results suggest that thalidomide can efficiently alleviate bone cancer pain and it may be a useful alternative or adjunct therapy for bone cancer pain."3.76Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-α expression in a mouse model. ( Gu, X; Ma, Z; Mei, F; Ren, B; Zhang, J; Zhang, R; Zheng, Y, 2010)
"In a series of 12 patients suffering from an HIV infection, including 9 with confirmed AIDS, who complained about pharyngeal pain in a fixed site, having a progressive intensity and not relieved by antalgics and the specific treatments that were prescribed empirically, and for whom etiological investigation yielded negative results, Thalidomide proved to be the only effective means of healing the exulcerated, nail-mark lesions or the ulcerated, budding, neoplastic-like lesions, and of completely suppressing pain."3.68[Mouth and pharyngeal hyperalgesic syndromes in AIDS]. ( Barry, B; Depondt, J; Gehanno, P; Gorin, I; Guedon, C; Leport, C; Poignonec, S, 1990)
"In an open study, 17 patients (16 women, 1 man) with refractory or severe rheumatoid arthritis were treated with thalidomide."3.67Treatment of refractory rheumatoid arthritis--the thalidomide experience. ( Gutiérrez-Montes, O; Gutiérrez-Rodríguez, O; Starusta-Bacal, P, 1989)
"Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24."2.78Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013)
" Phase 2 dosing was determined to be bortezomib 1."2.75Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. ( Anderson, KC; Avigan, DE; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, AJ; Joyce, R; Kaster, S; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Mazumder, A; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, DL; Weller, E; Xie, W, 2010)
"At diagnosis, although bone resorption markers were increased in more than 40% of the patients, only NTX (P = 0."2.72First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. ( Baccarani, M; Boni, P; Cangini, D; Cavo, M; Ceccolini, M; Cellini, C; Parente, R; Perrone, G; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E, 2006)
"Thalidomide was introduced as a sedative and antiemetic agent to the European market in the late 1950s."2.42[Novel potential uses of thalidomide in the management of pain? A review of the literature]. ( Bruera, E; Peuckmann, V; Strumpf, M; Zenz, M, 2003)
"Thalidomide has multiple actions, including anti-inflammatory and anti-angiogenic ones."2.42[Thalidomide--new prospective therapy in oncology]. ( Pałgan, I; Pałgan, K, 2003)
"Propranolol has anti-inflammatory effects that contribute to its antinociceptive action in the TMJ of females."1.48Anti-inflammatory effects of propranolol in the temporomandibular joint of female rats and its contribution to antinociceptive action. ( Dias, EV; Parada, CA; Sartori, CR; Tambeli, CH; Teixeira, JM; Zanelatto, FB, 2018)
"Since then, the patient has had two recurrences, coinciding with the reduction of thalidomide dosages, which were controlled by increasing the dose of the immunomodulator."1.48A Dramatic Case of Odynophagia. ( Diniz-Freitas, M; Diz, P; García-Caballero, L; Limeres, J; Seoane, J; Sopeña, B, 2018)
"Psoriasis is an immunodysregulatory inflammatory disease associated with comorbidities affecting quality of life."1.48Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry. ( Greenberg, JD; Guo, N; Holmgren, SH; Karki, C; Lebwohl, M; Mason, M; Strober, B, 2018)
"Multiple myeloma is an uncommon haematological cancer of plasma cells."1.48Multiple myeloma: Updated approach to management in 2018. ( Tomlinson, R, 2018)
"Kaposiform hemangioendothelioma is a rare vascular tumor of childhood that is locally aggressive but has little metastatic potential and by itself is not known to be lethal."1.35Kaposiform hemangioendothelioma in multiple spinal levels without skin changes. ( Bradeen, HA; Kalof, AN; Lisle, JW, 2009)
"Five patients complained of paresthesias and leg cramps."1.35Thalidomide and sensory neurotoxicity: a neurophysiological study. ( Arienti, S; Doria, A; Ermani, M; Rondinone, R; Zara, G, 2008)
"Thalidomide has been shown to selectively inhibit TNF-alpha production."1.31Analgesic effect of thalidomide on inflammatory pain. ( Cunha, FQ; Ferreira, SH; Ribeiro, RA; Vale, ML, 2000)
"In experiment 1, rats with the neuritis but not those with the myositis developed neuropathic pain symptoms."1.31A neuroimmune interaction in painful peripheral neuropathy. ( Bennett, GJ, 2000)

Research

Studies (40)

TimeframeStudies, this research(%)All Research%
pre-19904 (10.00)18.7374
1990's2 (5.00)18.2507
2000's11 (27.50)29.6817
2010's18 (45.00)24.3611
2020's5 (12.50)2.80

Authors

AuthorsStudies
da Silva, YK1
Augusto, CV1
de Castro Barbosa, ML1
de Albuquerque Melo, GM1
de Queiroz, AC1
de Lima Matos Freire Dias, T1
Júnior, WB1
Barreiro, EJ2
Lima, LM2
Alexandre-Moreira, MS1
Hernández, P1
Cabrera, M1
Lavaggi, ML1
Celano, L1
Tiscornia, I1
Rodrigues da Costa, T1
Thomson, L1
Bollati-Fogolín, M1
Miranda, AL1
González, M1
Cerecetto, H1
Deng, Y1
Wei, W1
Wang, Y1
Pan, L1
Du, G1
Yao, H1
Tang, G1
Niecke, A1
Peters, KM1
Alayli, A1
Lüngen, M1
Pfaff, H1
Albus, C1
Samel, C1
Hatemi, G1
Mahr, A1
Takeno, M1
Kim, D1
Melikoğlu, M1
Cheng, S1
McCue, S1
Paris, M1
Chen, M1
Yazici, Y1
Imai, K1
Sone, H1
Otomo, K1
Nakano, Y1
Hinoshita, F1
De Logu, F1
Trevisan, G1
Marone, IM1
Coppi, E1
Padilha Dalenogare, D1
Titiz, M1
Marini, M1
Landini, L1
Souza Monteiro de Araujo, D1
Li Puma, S1
Materazzi, S1
De Siena, G1
Geppetti, P1
Nassini, R1
Strober, B1
Karki, C1
Mason, M1
Guo, N1
Holmgren, SH1
Greenberg, JD1
Lebwohl, M1
Sopeña, B1
Limeres, J1
García-Caballero, L1
Diniz-Freitas, M1
Seoane, J1
Diz, P1
Zanelatto, FB1
Dias, EV1
Teixeira, JM1
Sartori, CR1
Parada, CA1
Tambeli, CH1
Chen, Y1
Luo, D1
Cai, JF1
Lin, CH1
Shen, Y1
Zou, J1
Guan, JL1
Tomlinson, R1
Yordanova, A1
Hose, D1
Neben, K1
Witzens-Harig, M1
Gütgemann, I1
Raab, MS1
Moehler, T1
Goldschmidt, H1
Schmidt-Wolf, IG1
Vozella, F1
Latagliata, R1
Carmosino, I1
Volpicelli, P1
Montagna, C1
Romano, A1
Roberto, A1
Finsinger, P1
Mancini, M1
Breccia, M1
Oliva, E2
Song, T1
Ma, X1
Gu, K1
Yang, Y1
Yang, L1
Ma, P1
Wang, W1
Zhao, J1
Yan, R1
Guan, J1
Wang, C1
Qi, Y1
Ya, J1
Sobell, JM1
Foley, P1
Toth, D1
Mrowietz, U1
Girolomoni, G1
Goncalves, J2
Day, RM2
Chen, R1
Yosipovitch, G1
Reich, K1
Gooderham, M1
Green, L1
Bewley, A1
Zhang, Z1
Khanskaya, I1
Shah, K1
Piguet, V1
Soung, J1
Popat, R1
Brown, SR1
Flanagan, L1
Hall, A1
Gregory, W1
Kishore, B1
Streetly, M1
Oakervee, H1
Yong, K1
Cook, G1
Low, E1
Cavenagh, J1
Khan, MI1
Ostadhadi, S1
Mumtaz, F1
Momeny, M1
Moghaddaskho, F1
Hassanipour, M1
Ejtemaei-Mehr, S1
Dehpour, AR1
Lisle, JW1
Bradeen, HA1
Kalof, AN1
Zhou, Y1
Garcia, MK1
Chang, DZ1
Chiang, J1
Lu, J1
Yi, Q1
Romaguera, J1
Delasalle, K1
Guo, Y1
Forman, A1
Fang, W1
Wang, M1
Richardson, PG1
Weller, E1
Lonial, S1
Jakubowiak, AJ1
Jagannath, S1
Raje, NS1
Avigan, DE1
Xie, W1
Ghobrial, IM1
Schlossman, RL1
Mazumder, A1
Munshi, NC1
Vesole, DH1
Joyce, R1
Kaufman, JL1
Doss, D1
Warren, DL1
Lunde, LE1
Kaster, S1
Delaney, C1
Hideshima, T1
Mitsiades, CS1
Knight, R1
Esseltine, DL1
Anderson, KC1
Wijermans, P1
Schaafsma, M1
Termorshuizen, F1
Ammerlaan, R1
Wittebol, S1
Sinnige, H1
Zweegman, S1
van Marwijk Kooy, M1
van der Griend, R1
Lokhorst, H1
Sonneveld, P1
Gu, X1
Zheng, Y1
Ren, B1
Zhang, R1
Mei, F1
Zhang, J1
Ma, Z1
O'Carroll, A1
O'Reilly, F1
Whitford, DL1
Peuckmann, V1
Strumpf, M1
Zenz, M1
Bruera, E1
HARRIS, SC1
ALLGOOD, JP1
Pałgan, K1
Pałgan, I1
DiNino, KC1
Tosi, P1
Zamagni, E1
Cellini, C1
Parente, R1
Cangini, D1
Tacchetti, P1
Perrone, G1
Ceccolini, M1
Boni, P1
Tura, S1
Baccarani, M1
Cavo, M1
Goli, V1
Zara, G1
Ermani, M1
Rondinone, R1
Arienti, S1
Doria, A1
MacPhail, L1
Ribeiro, RA1
Vale, ML1
Ferreira, SH1
Cunha, FQ1
Bennett, GJ1
Ciepłuch, H1
Baran, W1
Hellmann, A1
Gehanno, P1
Barry, B1
Depondt, J1
Guedon, C1
Poignonec, S1
Leport, C1
Gorin, I1
Gutiérrez-Rodríguez, O1
Starusta-Bacal, P1
Gutiérrez-Montes, O1
Eddy, NB1
Friebel, H1
Hahn, KJ1
Halbach, H1
Belda, W1
Manzoli, S1
Jordy, CF1

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel Group Study, Followed by an Active-treatment Phase to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Subjects With Active Behcet's Disease[NCT02307513]Phase 3207 participants (Actual)Interventional2014-12-30Completed
Analgesic Effects of Perioperative Propranolol Administration for Spine Surgery[NCT04421209]Phase 20 participants (Actual)Interventional2020-12-31Withdrawn (stopped due to No funding source)
A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis[NCT01690299]Phase 3250 participants (Actual)Interventional2012-10-01Completed
A Phase I/IIa Trial of VTD-panobinostat Treatment and Panobinostat Maintenance in Relapsed and Relapsed/Refractory Multiple Myeloma Patients[NCT02145715]Phase 1/Phase 254 participants (Anticipated)Interventional2013-01-31Active, not recruiting
A Prospective, Multicenter, Single Arm, Phase II Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone (BiRd Regimen) in the Treatment of the First Relapsed Multiple Myeloma[NCT04063189]Phase 2100 participants (Anticipated)Interventional2017-03-21Recruiting
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma[NCT02103335]Phase 138 participants (Actual)Interventional2014-06-05Completed
Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance[NCT01647165]Phase 20 participants (Actual)Interventional2012-07-11Withdrawn
A Pilot Study on the Efficacy of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive by Next Generation Flow[NCT03992170]Phase 250 participants (Anticipated)Interventional2018-12-31Recruiting
An Open-Label Phase I/II Study of the Safety and Efficacy of Bortezomib, Lenalidomide and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma[NCT00378105]Phase 1/Phase 268 participants (Actual)Interventional2006-09-30Active, not recruiting
A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma[NCT04009109]Phase 2188 participants (Anticipated)Interventional2020-10-21Recruiting
A Prospective, Observational Study, to Evaluate the Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for[NCT05218603]100 participants (Anticipated)Observational2021-11-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Area Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12)

The number of oral ulcers that was counted for the analysis of the primary endpoint included current and recurrent ulcers at each time point; a single oral ulcer could be recounted multiple times if it persisted or recurred at subsequent visits. (NCT02307513)
Timeframe: Oral ulcers were assessed at weeks 0 (baseline), 1, 2, 4, 6, 8, 10, and 12 during the placebo-controlled period.

InterventionUlcers*days (Least Squares Mean)
Placebo222.14
Apremilast 30 mg BID129.54

Change From Baseline in Behçet's Disease Quality of Life (BD Qol) Scores at Week 12

The Behçet's Disease Quality of Life questionnaire was developed to measure the influence of BD on a particpant's life. It consists of 30 self-completed itemized questions that measure disease-related restrictions on the participant's activities and their emotional response to these restrictions. The total score is the sum of all 30 items (each yes scores 1 and each no scores 0), with 0 representing no influence of Behçet's disease on a participant's quality of life and 30 representing the most severe influence. A negative change from baseline indicates improvement. (NCT02307513)
Timeframe: Baseline to week 12

InterventionUnits on a scale (Least Squares Mean)
Placebo-0.5
Apremilast 30 mg BID-3.5

Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Behçet's Disease Current Activity Index (BDCAI) at Week 12

The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The BDCAI consists of 12 questions regarding disease manifestations over the previous 4 weeks, including oral and genital disease activity, as well as other manifestations of BD involving the skin, joints, GI tract, eyes, nervous system, and vascular system. The BDCAI score is the sum score of 12 items and ranges from 0 to 12. A higher score indicates higher level of disease activity (worsening), and a negative change from baseline indicates improvement. (NCT02307513)
Timeframe: Baseline to week 12

InterventionUnits on a scale (Least Squares Mean)
Placebo-0.4
Apremilast 30 mg BID-0.9

Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Clinician's Overall Perception of Disease Activity at Week 12

The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The Clinician's Overall Perception of Disease Activity was assessed on a scale from 1 to 7, where a higher score indicates a higher level of disease activity and a negative change from baseline indicates improvement. (NCT02307513)
Timeframe: Baseline to week 12

InterventionUnits on a scale (Least Squares Mean)
Placebo-0.7
Apremilast 30 mg BID-1.6

Change From Baseline in Disease Activity as Measured by Behçet's Disease Current Activity Form (BDCAF): Patient's Perception of Disease Activity at Week 12

The Behçet's Disease Current Activity Form (BDCAF) consists of 3 component scores: the Behçet's Disease Current Activity Index (BDCAI) score, the Patient's Perception of Disease Activity, and the Clinician's Overall Perception of Disease Activity. The Patient's Perception of Disease Activity was assessed on a scale from 1 to 7, where a higher score indicates a higher level of disease activity and a negative change from baseline indicates improvement. (NCT02307513)
Timeframe: Baseline to week 12

InterventionUnits on a scale (Least Squares Mean)
Placebo-0.7
Apremilast 30 mg BID-1.7

Change From Baseline in Disease Activity as Measured by Behçet's Syndrome Activity Score (BSAS) at Week 12

The Behçet's Syndrome Activity Score (BSAS) contains 10 questions that assess the number of new oral and genital ulcers and skin lesions, GI, CNS, vascular, and ocular involvement, and the participant's current level of discomfort. The Behçet's Syndrome Activity Score ranges from 0 to 100, with a higher score indicating a higher level of disease activity. A negative change from baseline indicates improvement. (NCT02307513)
Timeframe: Baseline to week 12

InterventionUnits on a scale (Least Squares Mean)
Placebo-5.41
Apremilast 30 mg BID-17.35

Change From Baseline in Genital Ulcer Pain as Measured by VAS Score at Week 12

Pain of genital ulcers was measured using a 100 mm visual analog scale. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was recorded. A negative change from baseline indicates improvement. (NCT02307513)
Timeframe: Baseline to week 12

Interventionmm (Least Squares Mean)
Placebo-24.5
Apremilast 30 mg BID-30.0

Change From Baseline in Oral Ulcer Pain as Measured by Visual Analog Scale (VAS) at Week 12

"Pain of oral ulcers was measured using a 100 mm VAS scale. The participant was asked to draw a single line perpendicular to the VAS line at the point that represented the severity of their pain during the previous week, with 0 mm (the left-hand end of the scale) representing no pain and 100 mm (the right-hand end of the scale) representing the worst pain imaginable. The distance of the perpendicular line from the left-hand end of the scale was recorded.~A negative change from baseline indicates improvement." (NCT02307513)
Timeframe: Baseline to week 12

Interventionmm (Least Squares Mean)
Placebo-15.9
Apremilast 30 mg BID-40.7

Change From Baseline in the Total Score of the Static Physician's Global Assessment (PGA) of Skin Lesions of BD at Week 12

"BD-related skin lesions (including acne-like lesions, folliculitis, and erythema nodosum) were evaluated according to the Static Physician's Global Assessment as follows:~Score 0 = clear skin. Score 1 = mild in severity with the presence of 1 to 10 lesions (papules, pustules, cysts) or nodules at any anatomical site.~Score 2 = Moderate severity; presence of 11 to 20 nodules or lesions (papules, pustules, cysts) at any anatomical site.~Score 3 = Severe; presence of > 20 nodules or lesions (papules, pustules, cysts) at any anatomical site.~The total sore was calculated as the sum of the acne-like lesions, folliculitis, and erythema nodosum scores, and therefore ranges from 0 to 9, where a higher score indicates a higher level of activity. A negative change from baseline indicates improvement." (NCT02307513)
Timeframe: Baseline to week 12

Interventionscores on a scale (Least Squares Mean)
Placebo-0.8
Apremilast 30 mg BID-0.9

Number of Oral Ulcers Following Loss of Complete Response Through Week 12

Number of oral ulcers reported at the time of the first loss of complete response, ie, at the first instance when a participant had a reappearance of oral ulcers following a complete response, during the placebo-controlled treatment phase. (NCT02307513)
Timeframe: Baseline to week 12

Interventionoral ulcers (Least Squares Mean)
Placebo1.5
Apremilast 30 mg BID1.1

Percentage of Participants Who Achieved an Oral Ulcer Complete Response (Oral Ulcer-Free) by Week 6 and Remained Oral Ulcer-Free for at Least 6 Additional Weeks

Participants who were oral ulcer-free by week 6 and remained oral ulcer-free for at least 6 consecutive weeks during the 12-week placebo-controlled treatment phase. (NCT02307513)
Timeframe: Baseline to week 12

InterventionPercentage of participants (Number)
Placebo4.9
Apremilast 30 mg BID29.8

Percentage of Participants Who Experienced a Complete Response For Genital Ulcers at Week 12

A genital ulcer complete response at week 12 was defined as participants who were genital ulcer-free at week 12. (NCT02307513)
Timeframe: Week 12

InterventionPercentage of participants (Number)
Placebo41.2
Apremilast 30 mg BID70.6

Percentage of Participants Who Experienced an Oral Ulcer Complete Response at Week 12

A complete response at week 12 was defined as participants who were oral ulcer free at week 12. (NCT02307513)
Timeframe: Week 12

InterventionPercentage of participants (Number)
Placebo22.3
Apremilast 30 mg BID52.9

Percentage of Participants With no Oral Ulcers Following a Complete Response

The definition includes participants who remained oral ulcer-free through week 12 after achieving a complete response (oral ulcer-free) prior to week 12. (NCT02307513)
Timeframe: Baseline to week 12

InterventionPercentage of participants (Number)
Placebo13.2
Apremilast 30 mg BID31.3

Time to Oral Ulcer Resolution (Complete Response)

Time to oral ulcer resolution (defined as oral ulcer-free) was the time between the first dose date and the date when a complete response was achieved for the first time during the placebo-controlled treatment phase. For participants who did not achieve complete response or discontinued treatment before a complete response was achieved during the placebo-controlled treatment phase, time to event was censored at the last oral ulcer assessment date during the placebo-controlled treatment phase or the first dose date if there were no postbaseline ulcer assessments. Median and 95% confidence interval was based on Kaplan-Meier estimates. (NCT02307513)
Timeframe: Baseline to week 12

InterventionWeeks (Median)
Placebo8.1
Apremilast 30 mg BID2.1

Time to Recurrence of Oral Ulcers Following Loss of Complete Response

Time to recurrence of oral ulcers following the loss of complete response (oral ulcer-free) was defined as the first instance when a participant had a reappearance of oral ulcers following a complete response, during the placebo-controlled treatment phase. For participants who did not have oral ulcer recurrence or discontinued treatment before any oral ulcer recurrence during the placebo-controlled treatment phase, time to event was censored at the last oral ulcer assessment during placebo-controlled treatment phase; For participants without any oral ulcer assessment following the first complete response, time to event was censored to the first complete response date. (NCT02307513)
Timeframe: Baseline through week 12

InterventionWeeks (Median)
Placebo2.3
Apremilast 30 mg BID4.6

Number of Participants With TEAEs During the Apremilast-Exposure Period

"The apremilast-exposure period started on the date of the first dose of apremilast (week 0 for participants assigned to apremilast or week 12 for participants who were originally assigned to placebo and switched to apremilast at week 12) and ended 28 days after last dose in the active treatment phase.~An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. An SAE is any AE that resulted in death; was life-threatening; required or prolonged inpatient hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or constituted an important medical event. The investigator assessed the severity of each event according to the grading scale:~Mild: asymptomatic or mild symptoms; Moderate: symptoms causing moderate discomfort, local or noninvasive intervention indicated; Severe: symptoms causing severe discomfort or pain, requiring medical/surgical intervention (NCT02307513)
Timeframe: From first dose of apremilast (week 0 for those assigned to apremilast or week 12 for those assigned to placebo) up to 28 days after last dose; up to 56 weeks and 68 weeks in each arm respectively.

,
InterventionParticipants (Count of Participants)
Any TEAEAny Drug-related TEAEAny Severe TEAEAny Serious TEAEAny TEAE Leading to Drug InterruptionAny TEAE Leading to Drug WithdrawalAny TEAE Leading to Death
Apremilast/Apremilast9064171017120
Placebo/Apremilast7029471030

Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo-controlled Treatment Period

"A TEAE is an adverse event (AE) with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. A serious AE (SAE) is any AE that resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; or constituted an important medical event. For both AEs and SAEs the investigator assessed the severity of the event according to the grading scale:~Mild: asymptomatic or with mild symptoms; Moderate: symptoms causing moderate discomfort and local or noninvasive intervention is indicated; Severe: symptoms causing severe discomfort or pain, symptoms requiring medical/surgical intervention." (NCT02307513)
Timeframe: From first dose of study drug in the placebo-controlled phase to the first dose of apremilast in the active treatment phase (12 weeks) or up to 28 days after last dose for participants who did not receive study drug at week 12, whichever was earlier.

,
InterventionParticipants (Count of Participants)
Any TEAEAny Drug-related TEAEAny Severe TEAEAny Serious TEAEAny TEAE Leading to Drug InterruptionAny TEAE Leading to Drug WithdrawalAny TEAE Leading to Death
Apremilast 30 mg BID826063930
Placebo743764650

Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score In Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

"DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from Very Much (score 3) to Not at All or Not relevant (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if No, then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being A lot, A little, or Not at all (scores 2, 1, or 0 respectively). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best." (NCT01690299)
Timeframe: Baseline to Week 16

Interventionunits on a scale (Least Squares Mean)
Placebo-3.9
Apremilast 30mg Plus Placebo Injection-8.4
Etanercept 50mg Plus Placebo Tablet-7.8

Change From Baseline in the Mental Component Summary (MCS) Score of the Medical Outcome Study Short Form 36-item (SF-36) Health Survey Version 2.0 in Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

The SF-36 is a 36-item general health status instrument and consists of 8 scales: physical function (PF), role limitations-physical (RP), vitality (VT), general health perceptions (GH), bodily pain (BP), social function (SF), role limitations-emotional (RE), and mental health (MH). Scale scores range from 0 to 100, with higher scores indicating better health. Scores from the 8 scales were transformed to the norm-based scores using weights from U.S. general population to have a mean of 50 and variance = 10, with higher scores indicating better health. From these 8 scale, two overall summary scores were obtained - a Physical Component Summary score (PCS) and a Mental Component Summary score (MCS), both having the same mean of 50 and variance = 10 as noted for the individual scales for the U.S. general population, and with higher scores indicating better health. For MCS, change from baseline was calculated, where change = visit value - baseline value. (NCT01690299)
Timeframe: Baseline to Week 16

Interventionunits on a scale (Least Squares Mean)
Placebo2.6
Apremilast Plus Placebo Injection3.5
Etanercept Plus Placebo Tablets4.8

Percent Change From Baseline in the Affected Body Surface Area (BSA) for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

"BSA is a measurement of involved skin. The overall BSA affected by psoriasis was estimated based on the palm area of the participant's hand (entire palmar surface or handprint including the fingers), which equates to approximately 1% of total body surface area. BSA percent change from baseline was determined at each visit of the study, and is calculated as 100*(post-baseline BSA - baseline BSA) / baseline BSA." (NCT01690299)
Timeframe: Baseline to Week 16

Interventionpercent change (Least Squares Mean)
Placebo-16.3
Apremilast Plus Placebo Injection-47.7
Etanercept Plus Placebo Tablets-56.1

Percentage of Participants Who Achieved a 50% Improvement (Response) in the Psoriasis Area Severity Index (PASI-50) for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

PASI-50 response is the percentage of participants who achieved at least a 50% reduction (improvement) from baseline in PASI score at Week 16. The PASI score was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing. (NCT01690299)
Timeframe: Baseline to Week 16

Interventionpercentage of participants (Number)
Placebo33.3
Apremilast Plus Placebo Injection62.7
Etanercept Plus Placebo Tablet83.1

Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area and Severity Index (PASI) for the Comparison Between Etanercept 50mg SC QW and Placebo at Week 16

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing. (NCT01690299)
Timeframe: Baseline and Week 16

Interventionpercentage of participants (Number)
Placebo11.9
Etanercept 50mg Plus Placebo Tablet48.2

Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) for the Comparison Between Apremilast and Placebo at Week 16 From Baseline

PASI-75 response is the percentage of participants who achieved at least a 75% reduction (improvement) from baseline in PASI score at Week 16. The improvement in PASI score was used as a measure of efficacy. The PASI was a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomic regions of the body: head, trunk, upper limbs, and lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). The PASI score was set to missing if any severity score or degree of involvement was missing. (NCT01690299)
Timeframe: Baseline to Week 16

InterventionPercentage of participants (Number)
Placebo11.9
Apremilast Plus Placebo Injection39.8

Percentage of Participants Who Achieved a Lattice System Physician's Global Assessment (LS-PGA) Score of Clear (0) or Almost Clear at Week 16 in Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

The Lattice System Physician's Global Assessment is a global assessment performed by the investigator of psoriasis severity. Integrating ranges of BSA involvement with assessments of overall plaque severity (using a 4 point scale from none to marked for the signs of plaque elevation, erythema and scale), the LS-PGA produces an overall assessment of psoriasis severity on an 8-point scale, ranging from clear to very severe. To determine the final score, the lattice portion is governed by the BSA and among the plaque qualities, weights plaque elevation as most important, erythema next, and scale least. (NCT01690299)
Timeframe: Baseline to Week 16

Interventionpercentage of participants (Number)
Placebo6.0
Apremilast Plus Placebo Injection24.1
Etanercept Plus Placebo Tablets22.9

Percentage of Participants Who Achieved a Static Physician Global Assessment (sPGA) Score of Clear (0) or Almost Clear (1) With at Least 2 Points Reduction for Comparison Between Apremilast and Placebo and Etanercept and Placebo at Week 16

The sPGA is an assessment by the Investigator of the overall disease severity at the time of evaluation. The sPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), incorporating an assessment of the severity of the three primary signs of the disease: erythema, scaling and plaque elevation. When making the assessment of overall severity, the Investigator should factor in areas that have already been cleared (ie, have scores of 0) and not just evaluate remaining lesions for severity, ie, the severity of each sign is averaged across all areas of involvement, including cleared lesions. In the event of different severities across disease signs, the sign that is the predominant feature of the disease should be used to help determine the sPGA score. (NCT01690299)
Timeframe: Baseline and Week 16

Interventionpercentage of participants (Number)
Placebo3.6
Apremilast Plus Placebo Injection21.7
Etanercept Plus Placebo Tablet28.9

Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Apremilast-exposure Period

A TEAE in the apremilast-exposure phase is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes listed above. (NCT01690299)
Timeframe: From the first dose of apremilast (either Week 0 for participants originally randomized to apremilast or Week 16 for those originally randomized to placebo or etanercept who were switched to apremilast at week 16) until 28 days after last apremilast dose

,,
Interventionparticipants (Number)
Any TEAEAny Drug-related TEAEAny Severe TEAEAny Serious TEAEAny Serious Drug-related TEAEAny TEAE Leading to Drug InterruptionAny TEAE Leading to Drug WithdrawalAny TEAE Leading to Death
Apremilast/Apremilast71367621370
Etanercept/Apremilast5415741720
Placebo/Apremilast4523452830

Number of Participants With Treatment Emergent Adverse Events (TEAE) During the Placebo-Controlled Phase

A TEAE is an AE with a start date on or after the date of the first dose of study drug and no later than 28 days after the last dose of study drug for participants who discontinued early. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the patient's health, including laboratory test values, regardless of etiology. Any worsening (ie, clinically significant adverse change in frequency or intensity of a preexisting condition) should be considered an AE. A serious AE (SAE) is any untoward AE that is fatal, life-threatening, results in persistent or significant disability or incapacity, requires or prolongs existing in-patient hospitalization, is a congenital anomaly/birth defect, or is a condition that may jeopardize or may require intervention to prevent one of the outcomes above. (NCT01690299)
Timeframe: Week 0 to Week 16; mean duration of exposure was 14.90 weeks for placebo group, 15.13 weeks for apremilast group and 15.87 weeks for Etanercept group

,,
Interventionparticipants (Number)
Any TEAEAny Drug-related TEAEAny Severe TEAEAny Serious TEAEAny Serious Drug-related TEAEAny TEAE Leading to Drug InterruptionAny TEAE Leading to Drug WithdrawalAny TEAE Leading to Death
Apremilast Plus Placebo Injection5927332930
Etanercept Plus Placebo Tablets4421321320
Placebo4517200120

Psoriasis Flare/Rebound

Psoriasis flare is an AE and represents an atypical or unusual worsening of disease during treatment. It is defined as a sudden intensification of psoriasis requiring medical intervention or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is an AE and is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. This exacerbation is characterized by a PASI ≥125% of baseline or a new generalized pustular, erythrodermic, or more inflammatory psoriasis after stopping therapy. (NCT01690299)
Timeframe: Week 0 to Week 16; Placebo controlled phase

,,
Interventionparticipants (Number)
Any psoriasis flare captured as a TEAEAny psoriasis rebound captured as a TEAEThose with PASI ≥125% baseline score and D/C APR
Apremilast Plus Placebo Injection100
Etanercept Plus Placebo Tablets000
Placebo301

Psoriasis Flare/Rebound

Psoriasis flare is an AE and represents an atypical or unusual worsening of disease during treatment. It is defined as a sudden intensification of psoriasis requiring medical intervention or a diagnosis of new generalized erythrodermic, inflammatory, or pustular psoriasis. Rebound is an AE and is defined as a severe and sudden worsening of disease that occurs after treatment has been discontinued. This exacerbation is characterized by a PASI ≥125% of baseline or a new generalized pustular, erythrodermic, or more inflammatory psoriasis after stopping therapy. PASI ≥125% of baseline score at any visit after the last dose date for those who discontinued within the phase. (NCT01690299)
Timeframe: From the first dose of apremilast (either Week 0 or Week 16 for participants originally randomized to placebo or etanercept who were switched at Week 16) until 28 days after the last dose of apremilast.

,,
Interventionparticipants (Number)
Any psoriasis flare captured as a TEAEAny psoriasis rebound captured as a TEAEThose with PASI ≥125% baseline score and D/C APR
Apremilast/Apremilast420
Etanercept/Apremilast071
Placebo/Apremilast110

Estimated 18-month Overall Survival Rate

Overall survival was measured from treatment initiation to death, censored at the date patients were last known to be alive for those who had not died. (NCT00378105)
Timeframe: Survival rate at 18 months

InterventionPercentage of participants (Number)
All Patients97

Estimated 18-month Progression Free Survival (PFS) Rate

"PD from European Bone Marrow Transplant (EBMT) Response Criteria Required one or more:~>25% increased in the level of serum monoclonal paraprotein, which must also be an absolute increase of at least 5 g/L and confirmed on a repeat investigation, or >25% increased in 24-hour urinary light chain excretion (must also be an absolute increase of at least 200 mg/24 h and confirmed on a repeat investigation), or >25% increased in plasma cells in a bone marrow aspirate or biopsy (must also be an absolute increase of at least 10%) Definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas.~Development of new bone lesions or soft tissue plasmacytomas (not including compression fracture).~Development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause).~PFS was measured from treatment initiation to progression or death, censored at the date patients were last known to be alive and disease free" (NCT00378105)
Timeframe: PFS rate at 18 months

InterventionPercentage of participants (Number)
All Patients75

Objective Response Rate of the Drug Combination in This Patient Populations.

Overall Response (OR) was defined as partial response (PR) or better. Response was assessed according to European Group for Blood and Marrow Transplant criteria, modified to include nCR and VGPR, from the International Uniform Response Criteria. (NCT00378105)
Timeframe: Full response assessment was conducted at the end of cycle 8 (average of168 days) and after cycle 4 (84 days) for patients proceeding to transplant.

Interventionpercentage of participants (Number)
Phase 1 Population100
Phase II Population100
Total100

Percentage of Patients Who Remained in Response for More Than 18 Months

Duration of response was measured from first response to progression or death, censored at the date patients were last known to be alive and disease free for patients who had not progressed or died. (NCT00378105)
Timeframe: Response rate at 18 months

InterventionPercentage of participants (Number)
All Patients68

Reviews

6 reviews available for thalidomide and Ache

ArticleYear
Multiple myeloma, painful neuropathy, acupuncture?
    American journal of clinical oncology, 2009, Volume: 32, Issue:3

    Topics: Acupuncture Therapy; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Multiple Mye

2009
[Novel potential uses of thalidomide in the management of pain? A review of the literature].
    Schmerz (Berlin, Germany), 2003, Volume: 17, Issue:3

    Topics: Analgesics; Aspirin; Caffeine; Drug Therapy, Combination; Humans; Pain; Phenacetin; Thalidomide

2003
[Thalidomide--new prospective therapy in oncology].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2003, Volume: 56, Issue:9-10

    Topics: Analgesics; Angiogenesis Inhibitors; Antineoplastic Agents; Cachexia; Clinical Trials as Topic; Huma

2003
Does thalidomide have an analgesic effect? Current status and future directions.
    Current pain and headache reports, 2007, Volume: 11, Issue:2

    Topics: Animals; Humans; Neuroimmunomodulation; Pain; Thalidomide

2007
Topical and systemic therapy for recurrent aphthous stomatitis.
    Seminars in cutaneous medicine and surgery, 1997, Volume: 16, Issue:4

    Topics: Adjuvants, Immunologic; Administration, Topical; Adrenal Cortex Hormones; Analgesics; Anti-Inflammat

1997
Codeine and its alternates for pain and cough relief. 2. Alternates for pain relief.
    Bulletin of the World Health Organization, 1969, Volume: 40, Issue:1

    Topics: Amides; Analgesics; Animals; Antitussive Agents; Azepines; Carisoprodol; Cats; Chickens; Codeine; Co

1969

Trials

11 trials available for thalidomide and Ache

ArticleYear
A Randomized controlled clinical trial on dose optimization of thalidomide in maintenance treatment for recurrent aphthous stomatitis.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2022, Volume: 51, Issue:1

    Topics: Double-Blind Method; Humans; Pain; Recurrence; Stomatitis, Aphthous; Thalidomide

2022
Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.
    RMD open, 2022, Volume: 8, Issue:2

    Topics: Behcet Syndrome; Humans; Oral Ulcer; Pain; Quality of Life; Thalidomide

2022
Effectiveness and safety of Glycyrrhizae Decoction for Purging Stomach-Fire in Behcet disease patients: Study protocol for a randomized controlled and double-blinding trail.
    Medicine, 2018, Volume: 97, Issue:13

    Topics: Behcet Syndrome; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; D

2018
Sorafenib in patients with refractory or recurrent multiple myeloma.
    Hematological oncology, 2013, Volume: 31, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2013
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
    Acta dermato-venereologica, 2016, Volume: 96, Issue:4

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Male; Middle Aged; Pain; Pain Measur

2016
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2017, Volume: 31, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diarrhea; Double-Blind Method; Etanercept; Female; H

2017
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr

2016
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr

2016
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr

2016
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    The Lancet. Haematology, 2016, Volume: 3, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr

2016
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
    Blood, 2010, Aug-05, Volume: 116, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy

2010
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-01, Volume: 28, Issue:19

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie

2010
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-01, Volume: 28, Issue:19

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie

2010
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-01, Volume: 28, Issue:19

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie

2010
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-01, Volume: 28, Issue:19

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Kaplan-Meie

2010
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
    European journal of haematology, 2006, Volume: 76, Issue:5

    Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biom

2006
Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
    Medical science monitor : international medical journal of experimental and clinical research, 2002, Volume: 8, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc

2002

Other Studies

23 other studies available for thalidomide and Ache

ArticleYear
Synthesis and pharmacological evaluation of pyrazine N-acylhydrazone derivatives designed as novel analgesic and anti-inflammatory drug candidates.
    Bioorganic & medicinal chemistry, 2010, Jul-15, Volume: 18, Issue:14

    Topics: Analgesics; Animals; Anti-Inflammatory Agents; Arthritis; Ear; Edema; Female; Freund's Adjuvant; Hyd

2010
Discovery of new orally effective analgesic and anti-inflammatory hybrid furoxanyl N-acylhydrazone derivatives.
    Bioorganic & medicinal chemistry, 2012, Mar-15, Volume: 20, Issue:6

    Topics: Analgesics; Animals; Anti-Inflammatory Agents; Cell Line; Cyclooxygenase Inhibitors; Drug Design; Fe

2012
Health-related quality of life after 50 years in individuals with thalidomide embryopathy: Evidence from a German cross-sectional survey.
    Birth defects research, 2022, 08-01, Volume: 114, Issue:13

    Topics: Cross-Sectional Studies; Female; Fetal Diseases; Humans; Male; Pain; Quality of Life; Thalidomide

2022
Quality of life and pain in patients with thalidomide embryopathy in Japan.
    Molecular genetics & genomic medicine, 2020, Volume: 8, Issue:11

    Topics: Abnormalities, Drug-Induced; Adaptation, Psychological; Adult; Aged; Female; Humans; Japan; Male; Ma

2020
Oxidative stress mediates thalidomide-induced pain by targeting peripheral TRPA1 and central TRPV4.
    BMC biology, 2020, 12-14, Volume: 18, Issue:1

    Topics: Animals; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Pain; Rats; Rats, Sprague-D

2020
Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry.
    Journal of the American Academy of Dermatology, 2018, Volume: 78, Issue:2

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Body Surface Area; Comorb

2018
A Dramatic Case of Odynophagia.
    Dysphagia, 2018, Volume: 33, Issue:1

    Topics: Aged; Humans; Immunosuppressive Agents; Male; Pain; Recurrence; Stomatitis, Aphthous; Thalidomide

2018
Anti-inflammatory effects of propranolol in the temporomandibular joint of female rats and its contribution to antinociceptive action.
    European journal of pain (London, England), 2018, Volume: 22, Issue:3

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Analgesics; Animals; Anti-Inflammatory Ag

2018
Multiple myeloma: Updated approach to management in 2018.
    Australian journal of general practice, 2018, Volume: 47, Issue:8

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; beta 2-Microglobulin; Bortezomib; Disease Management;

2018
Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
    Hematological oncology, 2015, Volume: 33, Issue:1

    Topics: Aged; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Hematologic

2015
Thalidomide represses inflammatory response and reduces radiculopathic pain by inhibiting IRAK-1 and NF-κB/p38/JNK signaling.
    Journal of neuroimmunology, 2016, Jan-15, Volume: 290

    Topics: Animals; Cells, Cultured; Humans; Inflammation; Interleukin-1 Receptor-Associated Kinases; Male; MAP

2016
Thalidomide attenuates the development and expression of antinociceptive tolerance to μ-opioid agonist morphine through l-arginine-iNOS and nitric oxide pathway.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 85

    Topics: Animals; Arginine; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Tolerance; Gene Expressi

2017
Kaposiform hemangioendothelioma in multiple spinal levels without skin changes.
    Clinical orthopaedics and related research, 2009, Volume: 467, Issue:9

    Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers, Tumor; Celecoxib; Chil

2009
Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-α expression in a mouse model.
    Molecular pain, 2010, Oct-05, Volume: 6

    Topics: Animals; Behavior, Animal; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Injections, Int

2010
What has happened to people affected by thalidomide 50 years on?
    Irish journal of medical science, 2011, Volume: 180, Issue:2

    Topics: Activities of Daily Living; Adult; Arm; Disabled Persons; Female; Health Status; Humans; Leg; Male;

2011
Analgesia enhancing effect of thalidomide.
    Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1960, Volume: 103

    Topics: Analgesia; Glutamates; Humans; Pain; Pain Management; Thalidomide

1960
Rib pain and increased cough.
    Advance for nurse practitioners, 2005, Volume: 13, Issue:1

    Topics: Biopsy; Cough; Diagnosis, Differential; Humans; Male; Middle Aged; Multiple Myeloma; Nurse Practitio

2005
Thalidomide and sensory neurotoxicity: a neurophysiological study.
    Journal of neurology, neurosurgery, and psychiatry, 2008, Volume: 79, Issue:11

    Topics: Adult; Angiogenesis Inhibitors; Disability Evaluation; Female; Humans; Lupus Erythematosus, Cutaneou

2008
Analgesic effect of thalidomide on inflammatory pain.
    European journal of pharmacology, 2000, Mar-10, Volume: 391, Issue:1-2

    Topics: Acetates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Blocking; Carrageenan; Edema

2000
A neuroimmune interaction in painful peripheral neuropathy.
    The Clinical journal of pain, 2000, Volume: 16, Issue:3 Suppl

    Topics: Animals; Constriction, Pathologic; Cyclosporine; Dose-Response Relationship, Drug; Immunosuppressive

2000
[Mouth and pharyngeal hyperalgesic syndromes in AIDS].
    Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris, 1990, Volume: 107, Issue:5

    Topics: Acquired Immunodeficiency Syndrome; Adult; Female; Humans; Male; Middle Aged; Mouth Diseases; Pain;

1990
Treatment of refractory rheumatoid arthritis--the thalidomide experience.
    The Journal of rheumatology, 1989, Volume: 16, Issue:2

    Topics: Adult; Aged; Arthritis, Rheumatoid; Edema; Female; Humans; Male; Middle Aged; Pain; Sleep Stages; Th

1989
[Thalidomide in the control of pain in leprotic neuritis].
    Hospital (Rio de Janeiro, Brazil), 1966, Volume: 70, Issue:3

    Topics: Female; Humans; Leprosy; Male; Neuralgia; Neuritis; Pain; Thalidomide

1966
chemdatabank.com